Latest acute leukemia Stories
CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone...
SAN DIEGO, April 15, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that David R. Parkinson, M.D., has been appointed to the company's board of directors. Dr. Parkinson is a venture partner at New Enterprise Associates, a position he has held since 2012, and a member of the board of directors for Threshold Pharmaceuticals, a publicly-traded oncology company, and Zyngenia, Inc. He served as a director of Facet Biotech through its acquisition by Abbott in 2010....
ACGT today announced that seed money provided for innovative T-Cell immunotherapy cell and gene therapy research has led to two successful Clinical Trials for treatment of Acute Lymphoblastic Leukemia resulting in remissions in both children and adults who had no other hope of recovery. Stamford, Connecticut (PRWEB) April 08, 2013 Alliance for Cancer Gene Therapy, Inc. (ACGT), http://www.acgtfoundation.org, https://twitter.com/acgtfoundation, and https://www.facebook.com/acgtfoundation,...
WHITE PLAINS, N.Y., April 4, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency funding many of today's breakthroughs in blood cancer treatments, including advances in targeted therapies, immunotherapies and epigenetics. Many LLS-funded researchers will be presenting results of some of their latest work at the 104(th) AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center in Washington. D.C.,...
Two, 10-week fundraising campaigns supporting LLS's vision of a world without blood cancer will kick off in April SAN FRANCISCO, March 21, 2013 /PRNewswire-USNewswire/ -- The Greater Bay Area chapter of The Leukemia & Lymphoma Society (LLS) will launch its 23(rd) annual San Francisco Man & Woman of the Year fundraising campaign on April 4, 2013 at the University Club in San Francisco and its inaugural North Bay Man & Woman of the Year campaign on April 18, 2013 at a...
Brett Smith for redOrbit.com - Your Universe Online Job training can allow workers to take on new responsibilities and a team of oncologists from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York found that the same thing applies to the body’s immune system. By essentially taking T cells, a type of white blood cell, back to school – the oncologists were able to successfully eradicate a certain type of acute leukemia. Similar previous research has shown promise in young...
SEATTLE, March 4, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). Tosedostat is an oral aminopeptidase inhibitor which has been shown to deprive tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival....
500th XF Data Reference in Elsevier: Cell Stem Cell BILLERICA, Mass., Feb. 22, 2013 /PRNewswire/ -- Seahorse Bioscience, the leader in instruments and assay kits for measuring cell metabolism, announced a new milestone: the 500(th) journal reference including XF assay data. The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the March 7, 2013 issue of the journal Cell Stem Cell....
Finding emerged from 100 billion RNA nucleotides in 10 children with cancer After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked the disease's reemergence to specific genetic anomalies. The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study...
BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts the launch of new agents positioned for the treatment of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) through 2018. According to two Niche Markets and Rare Diseases reports, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, novel targeted therapies hold the most...
